

Accepted Manuscript

LINOLEIC ACID, GLYCEMIC CONTROL AND TYPE 2 DIABETES

Martha A. Belury , Rachel M. Cole , Deena B. Snoke ,
Taylor Banh , Austin Angelotti

PII: S0952-3278(18)30065-6
DOI: [10.1016/j.plefa.2018.03.001](https://doi.org/10.1016/j.plefa.2018.03.001)
Reference: YPLEF 1906



To appear in: *Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA)*

Received date: 7 March 2018
Accepted date: 7 March 2018

Please cite this article as: Martha A. Belury , Rachel M. Cole , Deena B. Snoke , Taylor Banh , Austin Angelotti , LINOLEIC ACID, GLYCEMIC CONTROL AND TYPE 2 DIABETES, *Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA)* (2018), doi: [10.1016/j.plefa.2018.03.001](https://doi.org/10.1016/j.plefa.2018.03.001)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Highlights:

- The n-6 fatty acid, linoleic acid, is associated with reduced risk for type 2 diabetes and insulin sensitivity

ACCEPTED MANUSCRIPT

LINOLEIC ACID, GLYCEMIC CONTROL AND TYPE 2 DIABETES

Martha A. Belury¹, Rachel M. Cole², Deena B. Snoke², Taylor Banh², Austin Angelotti²

¹Corresponding author: Program of Human Nutrition, 1787 Neil Avenue, 302 Campbell Hall, The Ohio State University, Columbus OH 43210 email: Belury.1@osu.edu Tel: 1-614-292-1680

²OSU Nutrition Graduate Program, Graduate School, The Ohio State University, Columbus OH

Key words:

Adiponectin

Insulin resistance

Linoleic acid

Monounsaturated fat

Polyunsaturated fat

Saturated fat

Funding: Ohio Agriculture Research and Development Center, Carol S. Kennedy endowment (College of Education & Human Ecology, OSU)

Abstract

Dietary fat quality, especially the intake of specific types of fatty acids, impacts the risk of many chronic diseases, including cardiovascular diseases, certain cancers and type 2 diabetes (T2DM). A recent pooled analysis involving 20 studies from around the world revealed that higher linoleic acid (18:2n-6 LA) biomarker is associated with dose-dependent decreases in the incidence of T2DM. This latest study corroborates earlier cross-sectional studies and intervention trials showing that biomarkers of LA intake are associated with reduced risk of T2DM and better glycemic control and/or insulin sensitivity. This review highlights key clinical trials that have evaluated the role of LA in glycemia and the related condition, insulin sensitivity.

Introduction

By 2050, an estimated one third of US adults will have type 2 diabetes mellitus (T2DM)[1]. Unfortunately, co-morbidities of T2DM include cardiovascular diseases, neuropathy, sleep apnea, blindness and depression, are all conditions that hasten mortality leading to 1 in 5 people dying as a result [1]. Pharmaceutical therapies for treating hyperglycemia in people with T2DM often have serious adverse side effects [2]. Lifestyle approaches offer alternative or complementary therapy to pharmaceutical treatment. Identifying dietary factors for managing hyperglycemia that are safe, effective, affordable and achievable is imperative to reduce the burden of T2DM on the health care system.

Dietary fat quality (i.e., the fatty acid composition) is a component of the diet that may affect the management of hyperglycemia in people with T2DM. Fats comprise ~1/3 of calories in the typical US diet with saturated fatty acids (SFAs) comprising ~ 35% monounsaturated fatty acids (MUFAs) ~40% , and polyunsaturated fatty acids (PUFAs) ~25% of fat energy. Higher intake of SFAs is generally related to increased risk of cardiometabolic diseases. In contrast, as early as 1994, studies have shown a consistent correlation between *higher* dietary or biomarker levels of the n-6 PUFA, linoleic acid (LA; 18:2n-6), and *lower* risk for T2DM [3-5]. A recent pooled analysis of 20 studies involving 39740 people from 10 countries showed that higher levels of LA in blood were associated with a 43% lower relative risk for T2DM [3]. The dose dependent decreases in T2DM were independent of age, BMI, sex, race or n3 PUFA levels, aspirin use or FADs polymorphisms.

Indeed, it appears that a higher intake of PUFAs, especially of LA is associated with improved glycemia. Over an average of a 5-year follow-up period, higher LA intake was associated with lower glycemia, measured by oral glucose tolerance tests, in nondiabetic men [6]. In addition, higher LA is associated with improved insulin sensitivity [7-9]. This review will summarize the literature evaluating LA biomarker status with glycemic control and highlight key clinical intervention studies evaluating the effect of LA-rich oils on glycemia and other T2DM-related conditions.

Clinical Studies Testing Fat Quality and Glycemia

Numerous studies have attempted to identify the impact of SFAs, MUFAs and PUFAs on hyperglycemia seen in T2DM. In a landmark randomized controlled trial, the KANWU study sought to substitute MUFA-rich foods in place of SFA-rich foods in 162 healthy men and women [10]. The goal was to determine whether a change of fat source from SFAs to MUFAs could alter insulin sensitivity. After 12 weeks, the SFA-rich diet resulted in impaired insulin sensitivity and the MUFA-rich diet had no effect. These data underscore a role of SFAs to worsen insulin sensitivity and a lack of a favorable effect of MUFA-rich diet on insulin sensitivity.

In attempts to evaluate a relationship of the MUFA, oleic acid (18:1n-9), in disease risk, some investigators have attempted to link the Mediterranean diet with decreased risk for cardiometabolic diseases. The Mediterranean diet is a dietary pattern characterized by higher intake of fruits, vegetables, legumes, fish, whole grains, nuts, and olive oil, a rich source of the MUFA, oleic acid. Indeed, this dietary pattern was associated with lower risk for cardiac disease and T2DM [11]. Yet, most studies fail to recognize that olive oil is not the sole dietary source of fatty acids in the Mediterranean diet; it is but one of many fatty acid sources in this dietary pattern. In fact, neither blood oleic acid levels nor the intake of MUFAs were associated with a change in T2DM risk in the Cardiovascular Health Study [12]. Further, in the PREDIMED study, there was no association of plasma oleic acid with reduced incidence of the metabolic syndrome [13]. The findings of the KANWU intervention study mirror findings from epidemiological and cross-sectional studies suggesting a *lack of SFAs* may be most impactful for modulating insulin resistance; whereas, adding MUFAs may have only a marginal, if any, effect. To our knowledge, a side-by-side trial comparing the effects of supplementing with MUFA-rich oil vs. SFA-rich oil on glycemia or insulin sensitivity in people with T2DM has not been conducted.

A meta-analysis of studies evaluating fish oil-derived long chain n-3 PUFAs, e.g., eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22: n-3), and glycemic control have found weak to no relationship between the two [14]; Interestingly, an effect of supplementation of EPA/DHA-rich oils may be relevant in people with metabolic syndrome but not relevant in non-obese, normo-glycemic people [14]. In

particular, randomized controlled trials testing EPA/DHA oils on insulin sensitivity failed to show an effect of n-3 PUFAs on glucose disposal when measured using the euglycemic-hyperinsulinemic clamp [15, 16]. Because some trials show that supplementation with EPA/DHA oils reduce inflammation [17], the usage of n-3 PUFAs to improve co-morbidities of T2DM, other than insulin resistance, might still be useful for people with T2DM.

Although there are inconsistent or null effects of MUFA and n-3 PUFA interventions on insulin resistance or glycemic control, several studies show *higher* LA levels in the diet or blood are associated with better insulin sensitivity [4, 7, 18, 19]. There have been a handful of randomized controlled trials testing the impact of LA-rich oils on insulin sensitivity or glycemic markers (summarized in **Table 1**). In a seminal study, adults were assigned to one of two diets in a crossover intervention to test LA-rich or SFA-rich foods [20] on insulin sensitivity as measured by a hyperinsulinemic-euglycemic clamp. Each diet period lasted five weeks. Compared to insulin sensitivity after the SFA diet period, insulin sensitivity was significantly better after five weeks consuming the LA-rich diet. Because LA-rich oil was substituted for SFAs, it was not possible to confirm that the effects of the LA-rich diet was attributed to LA or the lack of SFAs. In this study, women showed a reduction of visceral adipose mass measured by magnetic resonance imaging with the LA-rich oil; an effect of the LA-oil on visceral adipose mass in men was not evident [21].

In a more recent study, we conducted a randomized controlled crossover trial where women with T2DM were supplemented with either LA-oil or conjugated linoleic acid (CLA)-oil capsules for 16-week diet periods separated by a 4-week wash-out period [22, 23]. LA-oil supplementation resulted in significant improvements of glycemic control, e.g., fasting glucose and HbA1c, high-density lipoprotein and C-reactive protein. Furthermore, when women were supplemented with LA-oil, lean mass increased and trunk adipose mass was reduced as measured by dual x-ray absorptiometry. In our study, the effects of LA-oil were different than CLA-oil which had no impact on glycemia, high density lipoprotein, C-reactive protein, trunk adipose or lean mass [23]. Intriguingly, LA-oil supplementation increased plasma adiponectin, an adipokine often

associated with increased insulin sensitivity through peripheral effects on metabolism in muscle and liver.

In two newer interventions using food-based delivery of LA-oil, patients were provided instruction and foods containing LA-rich oils vs. SFA-rich fats to influence: 1) hepatic steatosis in overweight adults [24]; or 2) weight gain patterns in non-obese adults [25]. Compared to SFA-rich foods, LA-rich foods reduced hepatic steatosis and markers of inflammation [24]. When provided as additional calories that lead to weight gain, LA-rich foods increased lean mass accretion by almost 3-fold more than changes of lean mass in people fed SFA-rich fats [25]. These findings corroborate observational studies in cohorts where higher LA status (measured in diet, blood or adipose tissue) was associated with lower risk of T2DM [3-5, 26], better insulin sensitivity [4, 7, 18, 19], reduced trunk or visceral adipose mass [24, 25, 27], increased lean mass [19, 24, 25, 28, 29] and reduced markers of inflammation [19, 30, 31].

Because of the intriguing effects of LA-oils on insulin sensitivity [21] and body composition [19, 24, 25, 27], we recently completed a pilot study to determine the impact of LA-oil on plasma adiponectin and high molecular weight (HMW) adiponectin profiles [32]. HMW adiponectin is the bioactive form that stimulates mitochondria capacity in liver and skeletal muscles[33]. Post-menopausal women with the metabolic syndrome were enrolled into an open label, single-arm 16-week intervention. Participants were instructed to consume 10 g /d LA-rich oil by adding to foods such as yogurt, breakfast oatmeal and salad dressings. Biomarker levels of LA in erythrocytes were variable between subjects suggesting that compliance was also variable. However, plasma adiponectin and HMW-adiponectin increased and erythrocyte LA was associated with improved insulin sensitivity.

In a recent epidemiological study, plasma LA was associated with decreased intramyocellular lipid levels in older adults [34]. Interestingly, erythrocyte LA status declines approximately 10% per decade between the ages of 50 and 80 years [35]. The decline of LA status could contribute directly to the loss of insulin sensitivity that accompanies aging. To our knowledge this has not been tested.

The association of higher LA status with reduced risk for heart diseases [36-38] and T2DM [3-5], as well as a role of LA-oils to improve insulin sensitivity and modulate body

composition, argue for a key role of LA-rich oils to promote cardiometabolic health. Future studies are needed to identify optimal levels of dietary LA to reduce chronic diseases and deaths associated with insulin resistance and associated conditions.

ACCEPTED MANUSCRIPT

Table 1. Summary of Intervention Trials Testing Effects of LA-oils on Glycemic Control

Title/Citation	Cohort	Design/Dose/ Delivery of LA	Endpoints	Findings
Summers et al. (2002) [20]	N=17 Men & women (Non-obese, N=6; Obese, N=5; T2DM, N=6)	Cross-over design to study effect of SFAs vs. LA on insulin sensitivity 5-week diet periods of SFAs or LA delivered through foods Non-random order of fats Goal: To add ~5 g LA/d to achieve ~20 g LA/d (total)	Fatty acid composition, plasma Insulin sensitivity, clamp Visceral adipose, MRI	Plasma LA increased 10% after LA diet period LA increased insulin sensitivity and decreased visceral adipose
Norris et al. (2009) [23] Asp et al. (2011) [22]	N=55 Obese, postmenopausal women with T2DM Oral hypoglycemic medications	Cross-over design to study effect of LA vs. CLA on glycemia and body composition 16-week diet periods with 4-week wash-out period; LA or CLA delivered through capsule supplements Goal: To add ~6 g LA/d to achieve ~18 g LA/d (total)	Fatty acid composition, plasma Insulin resistance, HOMA-IR Body composition, DEXA Adipokines	Plasma LA increased 10% after LA diet period LA treatment decreased insulin resistance and trunk adipose and increased lean mass and adiponectin; CLA had no effect on these outcomes
Bjermo et al. (2012) [24]	N=67 centrally obese men and women with/without T2DM	10-week parallel arm to study liver steatosis SFAs vs. LA delivered	Fatty acid composition, serum Insulin resistance	Serum LA increased 11% after LA diet period LA group had decreased

		through foods Goal: To achieve ~21 g LA/d (total)	HOMA-IR Liver fat, MRI	liver fat with no change of insulin resistance (vs. SFA)
Rosqvist et al. (2014) [25] Iggman et al. (2014) [39]	N=39 Non-obese men & women	7-week parallel arm to study liver fat change after weight gain Over-feed subjects (+3%) SFAs vs. LA delivered through foods Goal: To Achieve ~17 g LA/d (total)	Fatty acid composition, plasma Body composition for liver fat, visceral adipose and muscle, MRI	Serum CE LA increased ~12% in LA-oil group LA decreased hepatic steatosis and increased lean mass gain (vs. SFAs)
Cole et al. (2016) [32]	N=15 women with MetS	16-week single-arm, non-blind to explore changes of oxylipin profile (not intent-to-treat) in relation to adiponectin Goal: To add 6 LA/d to achieve ~18 g LA/d (total)	Fatty acid composition, erythrocytes Oxylipin lipidomic analysis Adiponectin	Erythrocyte LA, no change LA increased, adiponectin, HMW adiponectin LA biomarker was associated with increased lean mass

Citations

1. Stokes, A., Preston, SH, *Deaths Attributable to Diabetes in the United States: Comparison of Data Sources and Estimation Approaches*. PLoS One, 2017. **12**(1): p. e0170219.
2. Chamberlain, J., Herman, WH, Leal, S, Rhinehart, AS, Shubrook, JH, Skolnik, N, Kalyani, RR, *Pharmacologic Therapy for Type 2 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes*. Ann Intern Med, 2017. **166**.
3. Wu, J., Marklund, M, Imamura, F, Tintle, N, Ardisson, Korat, AV, de Goede, J, Zhou, X, Yang, WS, de Oliveira, Otto MC, Kröger, J, Qureshi, W, Virtanen, JK, Bassett, JK, Frazier-Wood, AC, Lankinen, M, Murphy, RA, Rajaobelina, K, Del Gobbo, LC, Forouhi, NG, Luben, R, Khaw, KT, Wareham, N, Kalsbeek, A, Veenstra, J, Luo, J, Hu, FB, Lin, HJ, Siscovick, DS, Boeing, H, Chen, TA, Steffen, B, Steffen, LM, Hodge, A, Eriksdottir, G, Smith, AV, Gudnason, V, Harris, TB, Brouwer, IA, Berr, C, Helmer, C, Samieri, C, Laakso, M, Tsai, MY, Giles, GG, Nurmi, T, Wagenknecht, L, Schulze, MB, Lemaitre, RN, Chien, KL, Soedamah-Muthu, SS, Geleijnse, JM, Sun, Q, Harris, WS, Lind, L, Arnlöv, J, Riserus, U, Micha, R, Mozaffarian, D; Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Fatty Acids and Outcomes Research Consortium (FORCE), *Omega-6 fatty acid biomarkers and incident type 2 diabetes: pooled analysis of individual-level data for 39 740 adults from 20 prospective cohort studies*. Lancet Diabetes Endocrinol, 2017.
4. Riserus, U., Willett, WC, Hu, FB, *Dietary fats and prevention of type 2 diabetes*. Prog Lipid Res, 2009. **48**(1): p. 44-51.
5. Vessby, B., Aro, A, Skarfors, E, Berglund, L, Salminen, I, Lithell, H, *The risk to develop NIDDM is related to the fatty acid composition of the serum cholesterol esters*. Diabetes, 1994. **43**: p. 1353-7.
6. Mahendran, Y., Ågren, J, Uusitupa, M, Cederberg, H, Vangipurapu, J, Stančáková, A, Schwab, U, Kuusisto, J, Laakso, M, *Association of erythrocyte membrane fatty acids with changes in glycemia and risk of type 2 diabetes*. American Journal of Clinical Nutrition, 2014. **99**: p. 79-85.
7. Vessby, B., *Dietary fat and insulin action in humans*. Br J Nutr, 2000. **83 Suppl 1**: p. S91-6.
8. Fernandez-Real, J.M., et al., *Insulin resistance, inflammation, and serum fatty acid composition*. Diabetes Care, 2003. **26**(5): p. 1362-8.
9. Imamura, F., Micha, R, Wu, JH, de Oliveira Otto, MC, Otite, FO, Abioye, AI, Mozaffarian, D, *Effects of Saturated Fat, Polyunsaturated Fat, Monounsaturated Fat, and Carbohydrate on Glucose-Insulin Homeostasis: A Systematic Review and Meta-analysis of Randomised Controlled Feeding Trials*. Plos Med, 2016. **13**.
10. Vessby, B., Uusitupa, M, Hermansen, K, Riccardi, G, Rivellese, AA, Tapsell, LC, Nansen, C, Berglund, L, Louheranta, A, Rasmussen, BM, Calvert, GD, Maffetone, A, Pedersen, E, Gustafsson, IB, Storlien, LH., *Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: The KANWU Study*. Diabetologia, 2001. **44**(3): p. 312-9.
11. Salas-Salvadó, J., Guasch-Ferré, M, Lee, CH, Estruch, R, Clish, CB, Ros, E., *Protective Effects of the Mediterranean Diet on Type 2 Diabetes and Metabolic Syndrome*. Journal of Nutrition, 2016. **146**: p. 920S-927S.
12. Ma, W., Wu, JH, Wang, Q, Lemaitre, RN, Mukamal, KJ, Djoussé, L, King, IB, Song, X, Biggs, ML, Delaney, JA, Kizer, JR, Siscovick, DS, Mozaffarian, D, *Prospective association of fatty acids in the de novo lipogenesis pathway with risk of type 2 diabetes: the Cardiovascular Health Study*. American Journal of Clinical Nutrition, 2015. **101**: p. 153-63.
13. Mayneris-Perxachs, J., Guerendiain, M, Castellote, AI, Estruch, R, Covas, MI, Fitó, M, Salas-Salvadó, J, Martínez-González, MA, Aros, F, Lamuela-Raventós, RM, López-Sabater, MC; for PREDIMED Study Investigators, *Plasma fatty acid composition, estimated desaturase activities, and their relation with the metabolic syndrome in a population at high risk of cardiovascular disease*. Clinical Nutrition, 2014. **33**: p. 90-7.
14. Gao, H., Geng, T, Huang, T, Zhao, Q, *Fish oil supplementation and insulin sensitivity: a systematic review and meta-analysis*. Lipids in Health and Disease, 2017. **16**: p. 131.
15. Spencer, M., Finlin, BS, Unal, R, Zhu, B, Morris, AJ, Shipp, LR, Lee, J, Walton, RG, Adu, A, Erfani, R, Campbell, M, McGehee, RE Jr, Peterson, CA, Kern, PA., *Omega-3 fatty acids reduce adipose tissue macrophages in human subjects with insulin resistance*. Diabetes, 2013. **62**: p. 1709-17.

16. Akinkuolie, A., Ngwa, JS, Meigs, JB, Djoussé, L, *Omega-3 polyunsaturated fatty acid and insulin sensitivity: a meta-analysis of randomized controlled trials*. Clin Nutr, 2011. **30**: p. 702-7.
17. Lin N, S.J., Li YM, Zhang XY, Chen Y, Calder PC, Tang LJ., *What is the impact of n-3 PUFAs on inflammation markers in Type 2 diabetic mellitus populations?: a systematic review and meta-analysis of randomized controlled trials*. Lipids Health Dis, 2016. **15**.
18. Warensjo, E., et al., *Factor analysis of fatty acids in serum lipids as a measure of dietary fat quality in relation to the metabolic syndrome in men*. Am J Clin Nutr, 2006. **84**(2): p. 442-8.
19. Belury, M., Cole, RM, Bailey, BE, Ke, JY, Andridge, RR, Kiecolt-Glaser, JK., *Erythrocyte linoleic acid, but not oleic acid, is associated with improvements in body composition in men and women*. Mol Nutr Food Res, 2016.
20. Summers, L.K.M., et al., *Substituting dietary saturated fat with polyunsaturated fat changes abdominal fat distribution and improves insulin sensitivity*. Diabetologia, 2002. **45**(3): p. 369-77.
21. Summers, L., Fielding, BA, Bradshaw, HA, Ilic, V, Beysen, C, Clark, ML, Moore, NR, Frayn, KN, *Substituting dietary saturated fat with polyunsaturated fat changes abdominal fat distribution and improves insulin sensitivity*. Diabetologia, 2002. **45**(3): p. 369-77.
22. Asp, M., Collene, AL, Norris, LE, Cole, RM, Stout, MB, Tang, SY, Hsu, JC, Belury, MA., *Time-dependent effects of safflower oil to improve glycemia, inflammation and blood lipids in obese, post-menopausal women with type 2 diabetes: a randomized, double-masked, crossover study*. Clinical Nutrition, 2011. **30**: p. 443-9.
23. Norris, L.E., et al., *Comparison of dietary conjugated linoleic acid with safflower oil on body composition in obese postmenopausal women with type 2 diabetes mellitus*. Am J Clin Nutr, 2009. **90**(3): p. 468-76.
24. Bjermo, H., Iggman, D, Kullberg, J, Dahlman, I, Johansson, L, Persson, L, Berglund, J, Pulkki, K, Basu, S, Uusitupa, M, Rudling, M, Arner, P, Cederholm, T, Ahlström, H, Risérus, U., *Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial*. American Journal of Clinical Nutrition., 2012. **95**(5): p. 1003-12.
25. Rosqvist, F., Iggman, D, Kullberg, J, Cedernaes, J, Johansson, HE, Larsson, A, Johansson, L, Ahlström, H, Arner, P, Dahlman I, Risérus, U, *Overfeeding polyunsaturated and saturated fat causes distinct effects on liver and visceral fat accumulation in humans*. Diabetes, 2014. **63**(7): p. 2356-68.
26. Forouhi, N., Imamura, F, Sharp, SJ, Koulman, A, Schulze, MB, Zheng, J, Ye, Z, Sluijs, I, Guevara, M, Huerta, JM, Kröger, J, Wang, LY, Summerhill, K, Griffin, JL, Feskens, EJ, Affret, A, Amiano, P, Boeing, H, Dow, C, Fagherazzi, G, Franks, PW, Gonzalez, C, Kaaks, R, Key, TJ, Khaw, KT, Kühn, T, Mortensen, LM, Nilsson, PM, Overvad, K, Pala, V, Palli, D, Panico, S, Quirós, JR, Rodriguez-Barranco, M, Rolandsson, O, Sacerdote, C, Scalbert, A, Slimani, N, Spijkerman, AM, Tjonneland, A, Tormo, MJ, Tumino, R, van der A, DL, van der Schouw, YT, Langenberg, C, Riboli, E, Wareham, NJ., *Association of Plasma Phospholipid n-3 and n-6 Polyunsaturated Fatty Acids with Type 2 Diabetes: The EPIC-InterAct Case-Cohort Study*. PLoS Med, 2016.
27. Alsharari, Z., Risérus, U, Leander, K, Sjögren, P, Carlsson, AC, Vikström, M, Laguzzi, F, Gigante, B, Cederholm, T, De Faire, U, Hellénus, ML, Marklund, M, *Serum Fatty Acids, Desaturase Activities and Abdominal Obesity - A Population-Based Study of 60-Year Old Men and Women*. PLoS One, 2017. **12**(1): p. e0170684.
28. Welch, A., MacGregor, AJ, Minihane, AM, Skinner, J, Valdes, AA, Spector, TD, Cassidy, A., *Dietary fat and fatty acid profile are associated with indices of skeletal muscle mass in women aged 18-79 years*. The Journal of nutrition., 2014. **144**(3): p. 327-34.
29. Cardel, M., Lemas, DJ, Jackson, KH, Friedman, JE, Fernández, JR., *Higher Intake of PUFAs Is Associated with Lower Total and Visceral Adiposity and Higher Lean Mass in a Racially Diverse Sample of Children*. The Journal of nutrition., 2015. **145**(9): p. 2146-2152.
30. Fritsche, K., *The science of fatty acids and inflammation*. Advances in Nutrition, 2015. **15**: p. 293s-301s.
31. Perreault, M., Roke, K, Badawi, A, Nielsen, DE, Abdelmagid, SA, El-Sohemy, A, Ma, DW, Mutch, DM, *Plasma levels of 14:0, 16:0, 16:1n-7, and 20:3n-6 are positively associated, but 18:0 and 18:2n-6 are inversely associated with markers of inflammation in young healthy adults*. Lipids, 2014. **49**: p. 255-63.
32. Cole, R., Puchala, S, Ke, J-Y, Andridge, R, O'Donnell, B, Bradley, D, Belury, MA. *The Effect of Oils Rich in Linoleic Acid on Body Composition in Postmenopausal Women with Metabolic Syndrome*. . in *AOCS Annual Meeting*. 2016. Salt Lake City, UT.
33. Ruan, H., Dong, LQ., *Adiponectin signaling and function in insulin target tissues*. J Mol Cell Biol, 2016. **8**: p. 101-9.

34. Reinders, I., Song, X, Visser, M, Eiriksdottir, G, Gudnason, V, Sigurdsson, S, Aspelund, T, Siggeirsdottir, K, Brouwer, IA, Harris, TB, Murphy, RA., *Plasma phospholipid PUFAs are associated with greater muscle and knee extension strength but not with changes in muscle parameters in older adults*. The Journal of nutrition., 2014. **145**(1): p. 105-112.
35. Harris, W., Pottala, JV, Varvel, SA, Borowski, JJ, Ward, JN, McConnell, JP, *Erythrocyte omega-3 fatty acids increase and linoleic acid decreases with age: observations from 160,000 patients*. Prostaglandins Leukot Essent Fatty Acids, 2013. **88**(4): p. 257-63.
36. Oh, K., Hu, FB, Manson, JE, Stampfer, MJ, Willett, WC., *Dietary fat intake and risk of coronary heart disease in women: 20 years of follow-up of the nurses' health study*. Am J Epidemiol, 2005. **161**(7): p. 672-9.
37. Wang, D.D., et al., *Association of Specific Dietary Fats With Total and Cause-Specific Mortality*. JAMA Intern Med, 2016.
38. Harris, W., Mozaffarian, D, Rimm, E, Kris-Etherton, P, Rudel, LL, Appel, LJ, Engler, MM, Engler, MB, Sacks, F., *Omega-6 fatty acids and risk for cardiovascular disease: a science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention*. Circulation, 2009. **119**(6): p. 902-7.
39. Iggman, D., Rosqvist, F, Larsson, A, Arnlöv, J, Beckman, L, Rudling, M, Risérus, U, *Role of dietary fats in modulating cardiometabolic risk during moderate weight gain: a randomized double-blind overfeeding trial (LIPOGAIN study)*. J Am Heart Assoc, 2014. **15**: p. e001095.